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ELECTRONIC LETTER
Reduced penetrance alleles for Huntington’s
disease: a multi-centre direct observational
study
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Objective: To obtain penetrance data for Huntington’s disease
when DNA results are in the range of 36–39 CAG repeats and
assess the consistency of reporting the upper allele from two
reference centres.
Method: Data were collected anonymously on age of onset or
age last known to be unaffected from a cohort of individuals
with results in this range. DNA samples were re-analysed in
two reference centres. Kaplan-Meier analysis was used to
construct an age of onset curve and penetrance figures.
Results: Clinical data and concordant DNA results from both
reference centres were available for 176 samples; penetrance
figures (and 95% confidence intervals) for this cohort, at age 65
and 75 years, were 63.9% (55.5% to 73.2%) and 74.2%
(64.2% to 84.2%), respectively. Inclusion of 28 additional
subjects for whom repeat DNA results were unavailable,
obtained from only one reference centre, or discrepant by
one repeat within this range, gave penetrance data (including
95% confidence intervals) at ages 65 and 75 years of 62.4%
(54.4% to 70.4%) and 72.7.% (63.3% to 82.1%), respectively.
238 duplicate results were available from the reference centres;
10 (4.2%) differed by one CAG repeat in the reporting of the
upper allele and in two (0.84%) of these cases the discrepancy
was between 39 and 40 repeats.
Conclusion: When DNA results are in this range, a conserva-
tive approach is to say that there is at least a 40% chance the
person will be asymptomatic at age 65 years and at least a
30% chance the person will be asymptomatic at age 75 years.
H
untington’s disease is an autosomal dominant progres-
sive neurodegenerative disorder characterised by a move-
ment disorder (often choreiform in nature), a disturbance
of affect and a selective cognitive deficit. In 1993, an unstable
expansion of a CAG sequence in the first exon of the gene IT15
was identified as the pathological mutation.1 Soon after the
identification of the gene, it was realised that there was a
negative correlation between the age of onset and the size of the
CAG repeat length, but the wide spread of age of onset for each
repeat size effectively made this of limited clinical value; these
data have been summarised in reviews.2 3
A number of reports have shown that in the size range of 36–
39 repeats the age of onset could either be very late or not occur
at all.4–6 In 1998, the American College of Medical Genetics and
the American Society of Human Genetics (ACMG/ASHG)
suggested that service laboratories should use the following in
reporting results: under 27 repeats, unequivocally normal;
27–35 repeats, normal but may expand in future generations;
36–39 repeats, abnormal but associated with reduced pene-
trance; 40 or more repeats, abnormal.7 At that time empiric
penetrance risks were unavailable. A study by Brinkman et al
using direct observations and a Kaplan-Meier analysis failed to
give an adequate estimate of the reduced penetrance because of
small numbers in the reduced penetrance size range of 36–39
repeats.8 The same group analysed a larger data set but
extrapolated the information on age of onset curves from data
obtained in the range of 41–56 repeats; the authors argued that
individuals with results in this size range may not present to
medical attention and a direct approach may overestimate the
penetrance of these alleles.9 For the most part, service
laboratories only investigate samples of DNA from families in
which Huntington’s disease has occurred or is strongly
suspected. This study was undertaken to obtain an age of
onset curve for Huntington’s disease with allele sizes of 36–39
repeats using a direct observational approach.
METHODS
Sample collection
Ethical approval (Trent MREC02/4/062) was granted for
obtaining completely anonymised clinical data and aliquots of
DNA from genetics departments offering diagnostic and
predictive tests for Huntington’s disease. Collaborating centres
were given data sheets with unique identifying numbers which
were used to report gender, age of onset of Huntington’s
disease or the age at which the individual was last known to be
unaffected and brief pedigree details for their results in the 36–
39 repeat range. This form was returned together with an
aliquot of DNA labelled with the same unique number. No
record was kept of the genetic department which sent the data
and samples. The DNA samples were then re-analysed in two
UK laboratories at Sheffield and Edinburgh, hereafter called the
reference centres. It was not possible to trace any discrepancies
back to an individual or a collaborating centre.
DNA analysis in the reference centres
PCR amplification of the CAG repeat in the IT15 gene was
performed after the method of Warner et al10 but modified to
use a fluorescently labelled HD1 primer. Fluorescently labelled
products were run on a 48 capillary Applied Biosystems 3730
DNA analyser (Applied Biosystems, Foster City, CA) and CAG
repeat sizes determined by direct visual analysis of the
fluorescent profile using Applied Biosystems GeneMapper
software.
Statistical analysis
All individuals, including both those affected and asympto-
matic at-risk, were included to calculate the cumulative
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probability of disease onset by a particular age using Kaplan-
Meier survival analysis. Individuals with a CAG repeat length of
36–39 repeats were the cohort at risk from birth to diagnosis of
disease or last known contact age (censored). The Kaplan-
Meier survival curves were compared by the log-rank test




A total of 263 samples were received: 110 were from males and
151 from females, and in two cases the gender was not
reported. Eight samples were excluded because the clinical data
were missing, 11 samples sent in error with under 36 repeats
were eliminated, and 40 samples were excluded because they
were over 40 repeats. Of the remaining 204 samples, there were
16 cases where no DNA was sent or a result could not be
obtained in either reference centre, there were five cases where
a result was obtained from only one reference centre, and there
were seven cases where the results from the reference centres
differed by one repeat within the reduced penetrance range
(these 28 cases were included in table 1 based on the result
from the referring laboratory agreeing with the result from one
of the reference centres). The effect of removing theses 28
samples is shown in table 2.
There were no significant differences between the different
age of onset curves when the analysis included the 28 samples
with repeat results which were absent, obtained from one
reference centre or discrepant by one CAG repeat (log-rank
test = 5.7, df = 3, p = 0.13). However, there were significant
differences between the curves when these samples were
excluded (log-rank test = 8.5, df = 3, p = 0.036) (fig 1).
Table 3 shows the cumulative probability of the age of onset
of Huntington’s disease by age and CAG repeat size for ages 65–
75 years.
A trend of increasing penetrance with increase in repeat size
was expected. Table 3 shows this was not the case: the
penetrance figures for 38 repeats were significantly higher
(fig 1). The effect was still present when the data for 36–38
repeats were aggregated as penetrance was higher than for 39
repeats alone. This may be the effect of studying small
numbers: there were 13 affected cases, with a mean age of
onset of 52.0 years, and 33 unaffected cases in the first analysis
(table 2). When the additional 28 samples were included, the
number of affected cases increased to 17, with a mean age of
onset of 55.7 years, and the number of unaffected cases
increased to 35; this resulted in the penetrance for 38 repeats
still being high but the statistical significance between the
curves was lost. Therefore, only one age of onset curve was
drawn (fig 2).
When the analysis was based strictly on the original protocol
of concordant data between the two reference centres,
penetrance figures (and 95% confidence intervals) for ages 65
and 75 years for individuals with results in the range of 36–39
repeats were 63.9% (55.5% to 73.2%) and 74.2% (64.2% to
84.2%), respectively. When the additional 28 samples were
included, penetrance figures (and 95% confidence intervals) at
ages 65 and 75 years were 62.4% (54.4% to 70.4%) and 72.7%
(63.3% to 82.1%), respectively.
As sib-sib pairs tend to have a similar age at onset for given
expanded repeat sizes,11 we assessed the possible bias intro-
duced by the inclusion of first degree relative pairs (sib-sib and
parent-child) by randomly selecting one of the pair for
exclusion from the survival analysis. There was no significant
difference in the results obtained, suggesting that their
inclusion did not introduce major bias.
Issues at the 36 repeat and 40 repeat boundaries
There was no issue at the 36 repeat boundary; the reference
centres found no case sent as >36 repeats to have a lower
repeat number.
A total of 40 samples were excluded from the analysis
because one or both reference centres gave a result of >40
repeats. In three cases a repeat result could not be obtained
from both reference centres and in one case the collaborating
centre sent in a sample with 43 repeats. The style of reporting
varied between collaborating centres: six gave a range which
included 40 or more repeats; however, there were 24 cases in
which the collaborating centres unequivocally reported a result
in the reduced penetrance range and both reference centres
gave a result of 40 repeats. In addition, there were two cases
where the collaborating centres reported 39 repeats, but there
was discordance of one allele between the reference centres:







Range in age of
onset (years) Unaffected Mean age (years) Range (years)
36 21 10 59.4 38–79 11 42.5 23–68
37 46 22 60.3 48–74 24 47.5 21–85
38 52 17 55.7 40–75 35 48.2 25–76
39 85 43 62.1 31–89 42 48.7 20–79
Total 204 92 112








Range in age of
onset (years) Unaffected Mean age (years) Range (years)
36 18 9 59.4 38–79 9 42.5 23–68
37 39 19 60.6 48–74 20 48.5 21–85
38 46 13 52.0 40–75 33 48.0 25–76
39 73 35 64.1 38–89 38 48.7 20–79
Total 176 76 100
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one gave a result which was 39 repeats and the other gave a
result of 40 repeats.
There were four samples with two abnormal alleles;
essentially, one was in the low penetrance range and the other
was over 40 repeats. In one of these, three alleles were
observed; the collaborating centre gave a result of 17, 36 and 41.
This was confirmed in the reference centres although there was
a discrepancy of one repeat in the reporting of the lower allele.
In the other three samples there was concordance with the
collaborating and reference centres giving results of 37 and 43
repeats, 38 and 42 repeats, and 38 and 45 repeats.
Discrepancies in reporting the upper alleles
It was not possible to obtain a repeat DNA result from both
reference centres for 24 of the 263 cases sent from the
collaborating centres. One sample without adequate clinical
data was excluded from the penetrance study but the reporting
centre gave the result as 36 and 37 repeats whereas the
reference centres gave the result as 38 and 38 repeats, and 38
and 38 or 38 and 39 repeats. Excluding this sample, there were
238 cases where duplicate results were obtained from both
reference centres and of these 10 (4.2%) differed by one CAG
repeat in the reporting of the upper allele. This would only have
made a difference to the interpretation of the result in the two
cases (0.84%) where the discrepancy was between 39 and 40
repeats.
DISCUSSION
A large body of data concerning the 36–39 repeat range was
analysed in this study. The excess of samples from females may
represent the fact that more females come forward for
predictive tests.12 These data were generated from individuals
with a family history of Huntington’s disease and should not be
applied in the case of an allele of this size being detected in an
otherwise healthy individual; for example, testing the partner
of an at-risk individual as part of an exclusion test or for pre-
implantation diagnosis.
Identification of a reduced penetrance allele relies on either a
symptomatic individual coming to medical attention or an
asymptomatic individual deciding to have a predictive test and
the result being in the range of 36–39 repeats. This may result
in an overestimate of the penetrance as more affected
individuals may come to attention compared with elderly
asymptomatic individuals requesting a predictive test. In an
earlier study, Langbhen et al extrapolated information on
penetrance based on age of onset curves in a group of
individuals with 41–56 repeats.9 They estimated penetrance
data at age 75 years of 14%, 26%, 45% and 60% at 36, 37, 38 and
39 repeats, respectively. This method makes allowance for
missing alleles in this range, but assumptions have to be made.
If, in addition to missing alleles, there are other factors to
account for the data in the range of 36–40 repeats not fitting
their mathematical model, then it is possible that the number
of missing alleles was overestimated and the penetrance
underestimated.
The bias towards an overestimate of penetrance in this report
is shown by the effect of having relatively few affected
individuals with 38 repeats compared with asymptomatic
individuals. It may be that this occurred by chance; however,
as expected, there was a trend towards increasing the number
of samples with each CAG repeat size. It is difficult to identify a
plausible alternative explanation but the possible existence of
one must remain open for the present.
A discrepancy of one CAG repeat within the four main ACMG/
ASHG groups is not clinically significant. There were 24 cases
where the collaborating centre unequivocally reported a low
penetrance allele and both reference centres gave a result of 40
repeats. Taken together with the 176 results in table 2, this
represents 12.0% of cases unequivocally intended to be reported
as being in the reduced penetrance range and having concordant
results from the reference centres. Although high, it is to be
remembered that these samples were reported from as early as
1994 and multiple laboratory methods were used. It is interesting
to note that in this large cohort there was a discrepancy of one
CAG repeat in reporting the upper allele between the reference
centres in 4.2% of cases; in two (0.84%) of these cases the
discrepancy was at the 39 and 40 repeat boundary which would
represent a misclassification. If the 24 samples intended to be
reported in the reduced penetrance range were included in the
analysis, penetrance figures (and 95% confidence intervals)
would have been 49.4% (38.0% to 60.8%) at age 65 years and
55.8% (42.7% to 68.9%) at age 75 years.
The discrepancy in data between the reference centres in this
study can be compared with results from a European pilot
quality assessment scheme in which a variation of ¡1 CAG in
the range up to 40 repeats and¡3 CAG repeats for results over































Figure 1 Cumulative age of onset curves for Huntington’s disease alleles
in the range of 36–39 repeats based on 176 samples for which clinical
data and concordant DNA results were available from two reference
laboratories.
Table 3 Cumulative probability (%) of age of onset of Huntington’s disease by CAG repeat size based on the 176 results with
concordant DNA results from both reference centres
Age (years) 36 (repeats) 37 (repeats) 38 (repeats) 39 (repeats) 36–38 (repeats) 36–39 (repeats)
65 66.3 (34.4 to 98.2) 56.4 (36.4 to 76.4) 83.5 (71.2 to 95.8) 56.9 (44.2 to 69.6) 70.1 (58.7 to 81.5) 63.9 (55.5 to 73.2)
70 66.3 (34.4 to 98.2) 56.5 (36.4 to 76.4) 88.2 (75.8 to 100) 59.8 (46.7 to 72.9) 74.1 (61.8 to 86.4) 67.1 (58.2 to 75.9)
75 66.3 (64.2 to 84.2) 78.2 (46.4 to 100) 96.1 (86.3 to 100) 63.8 (49.9 to 77.7) 87.0 (72.9 to 100) 74.2 (64.2 to 84.2)
Data in parentheses are 95% confidence intervals.
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on six DNA samples from five families. Despite the allowed
limits, 6.2% of alleles were reported outside these limits and in
one case there would have been a significant misdiagnosis
between the normal and pathological range.
Another potential bias in this study is that there may be some
samples reported in the collaborating centre as 40 repeats
which could have been reclassified as 39 repeats. This
information is unknown and could not be obtained without
dramatically increasing the size of the study.
Although the mean age of onset and CAG repeat size are
negatively correlated, for any particular CAG repeat size there is
wide spread in age of onset. This is reflected in this data set as
the spread of ages of onset for both 39 repeats and the whole
cohort was 31–89 years (table 1). Apart from the CAG repeat
length, other factors, both genetic and non-genetic, influence
the age of onset.14
A patient with an abnormal predictive test result cannot be
given accurate information regarding age of onset based on the
repeat size. There is variation between laboratories and
clinicians as to how results are reported; some laboratories do
not report the actual repeat size but only the main category as
set out by the ACMG/ASHG; others report the actual repeat size
to the clinician who may or may not disclose it to the family.
The reason for caution in disclosing the actual result is that it
does not add useful information for the individual and has the
potential to be misinterpreted.
The onset of Huntington’s disease is insidious and difficult to
determine accurately. While every effort was made to check the
DNA result, age of onset data were based on estimates from
multiple collaborating centres; it is likely that the rigour of that
estimation varied both within and between centres.
Given these various constraints and the bias towards over-
estimating penetrance, we would argue that broad-based
conservative statements are made regarding age of onset. We
suggest that if a result is found in the range of 36–39 repeats in
the context of a predictive test, there is at least a 40% chance
the person will be asymptomatic at age 65 years and at least a
30% chance the person will be asymptomatic at age 75 years.
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